Company intelligence / Profile preview
VESSL Therapeutics
Haifa, Haifa District, Israelvessltherapy.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
VESSL Therapeutics has completed two early-stage clinical trials demonstrating safety and initial efficacy of its cell/gene therapy products. The company raised $16M in Series AA funding to advance MGA into a larger Phase IIB trial for peripheral arterial disease, and MGG into a first-in-human study for hemodialysis patients. Their approach uses autologous vascular cells modified with angiogenic genes to promote new blood vessel growth or improve dialysis graft function.
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
RunYoung Capital (financing round leader)
Beyond the preview
Go deeper on VESSL Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VESSL Therapeutics.